Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper ...

The mass rollout of weight loss injections on the NHS in England began in June. It means GPs are allowed to prescribe the ...

Mayo Clinic also notes that colon cancer symptoms can also present themselves with more frequent diarrhoea or constipation, ...

Danish drugmaker Novo Nordisk is working to bring its blockbuster drug Ozempic to India “as soon as possible", Dr Yan Cai, ...

India is among the top two countries in terms of type 2 diabetes cases and third in terms of obesity; hence, the need for ...

UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts Zepbound sales could exceed market expectations by roughly 15%. Meanwhile, ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.